Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

Development of new recombinant vaccines for rabies and dog population management

Thesis (PhD (Micobiology))--Univeristy of Pretoria, 2019

Saved in:
Bibliographic Details
Other Authors: Nel, Louis Hendrik.
Format: Thesis
Language:English
Published: University of Pretoria 2026
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867613481090416640
access_status_str Open Access
author2 Nel, Louis Hendrik.
author_browse Nel, Louis Hendrik.
author_facet Nel, Louis Hendrik.
collection Thesis
dc_rights_str_mv © 2025 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. No part of this work may be reproduced or transmitted in any form or by any means, without the prior written permission of the University of Pretoria.
description Thesis (PhD (Micobiology))--Univeristy of Pretoria, 2019
format Thesis
id oai:repository.up.ac.za:2263/110471
institution University of Pretoria (South Africa)
language English
last_indexed 2026-06-10T12:36:49.885Z
license_str Other — see source repository
provenance_str_mv Harvested via OAI-PMH from UPSpace — University of Pretoria Institutional Repository
publishDate 2026
publishDateRange 2026
publishDateSort 2026
publisher University of Pretoria
publisherStr University of Pretoria
record_format dspace
source_str UPSpace — University of Pretoria Institutional Repository
spelling oai:repository.up.ac.za:2263/110471 Development of new recombinant vaccines for rabies and dog population management Nel, Louis Hendrik. nicolette.wright@up.ac.za Wright, Nicolette UCTD Sustainable Development Goals (SDGs) Immunocontraceptive Rabies Vaccine Adenomas Recombinant Thesis (PhD (Micobiology))--Univeristy of Pretoria, 2019 Development of new recombinant vaccines for rabies and dog population management Domestic dogs are responsible for the majority of human rabies cases. To eliminate rabies from a given population, two components are crucial, namely mass vaccination of dogs and provision of PEP to bite victims. Achieving the recommended 70% vaccination coverage can be difficult in developing countries. This study aimed to develop recombinant vaccines that could address two factors that hinder the success of vaccination campaigns: 1) vaccinating unreachable dogs and 2) preventing high population turnover. In considering the first aim, oral vaccination of dogs in developing countries can be a useful adjunct in remote areas or communities with large numbers of free-roaming dogs. Given its host specificity (canines), transmission mechanism (oral) and safety, a recombinant canine adenovirus type 2 expressing the rabies glycoprotein gene (CAV2- RG) could be an ideal candidate oral vaccine. To assess the potential use of this vaccine in dog populations, we investigated the prevalence of antibodies against canine adenovirus type 2 (CAV2) in South African dogs. Blood was collected from 241 dogs from 2 provinces in South Africa. Sampled dogs had not previously been vaccinated against canine adenovirus (CAV1 or CAV2). The high seropositivity observed (45% and 62%) in animals from both provinces suggests that CAV2 circulates extensively among domestic dogs in South Africa. Given this finding, we evaluated the effect of pre-existing CAVspecific antibodies on the efficacy of the CAV2-RG vaccine in dogs. Purpose-bred Beagle dogs, which received prior vaccination against CAV, were immunized by oral administration of CAV2-RG. After rabies lyssavirus (RABV) infection, all animals, except one vaccinated dog, developed rabies. This study demonstrated that pre-existing antibodies against CAV, such as naturally occurs in South African dogs, inhibits the development of neutralizing antibodies against RABV when immunized with a CAV-based rabies recombinant vaccine. Considering the second aim of this study, high population turnover in free-roaming dogs is a major factor that influences the efficiency and cost of vaccination programmes. As a population management intervention, surgical sterilization is cost-prohibitive in developing countries while chemical sterilization presents many difficulties associated with safety and acceptance of such practices. Immunocontraceptives may offer an ideal, non-permanent mechanism to interrupt breeding cycles and contribute to population management. We have therefore developed 6 candidate immunocontraceptive vaccines expressing gonadotropin-releasing hormone (GnRH). Two human adenovirus type 5 (HAd5) vaccines and four DNA-based vaccines were constructed. Expression of the GnRH-gene from all inserts was confirmed in cell culture and vaccines were evaluated for immunogenicity in a murine model. No animals developed anti-GnRH antibody responses after 2 intramuscular doses of the DNA vaccines. In a heterologous primeboost strategy all animals that received DNA vaccines also received a booster dose of one HAd5 vaccine but failed to develop any anti-GnRH antibodies. After 2 intramuscular vaccinations with the respective HAd5 constructs, mice from both groups developed GnRH-specific antibody responses. This study demonstrated the potential of recombinant viral vectored vaccines to induce an antibody response against GnRH. These findings may represent an important step in the development of an effective immunocontraceptive vaccine for use in domestic dogs Biochemistry, Genetics and Microbiology (BGM) PhD (Microbiology) Unrestricted Faculty of Natural and Agricultural Sciences SDG-03: Good health and well-being 2026-06-08T09:44:06Z 2026-06-08T09:44:06Z 2019-04 2019-02 Thesis * A2019 http://hdl.handle.net/2263/110471 N/A en © 2025 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. No part of this work may be reproduced or transmitted in any form or by any means, without the prior written permission of the University of Pretoria. application/pdf University of Pretoria
spellingShingle UCTD
Sustainable Development Goals (SDGs)
Immunocontraceptive
Rabies
Vaccine
Adenomas
Recombinant
Development of new recombinant vaccines for rabies and dog population management
title Development of new recombinant vaccines for rabies and dog population management
title_full Development of new recombinant vaccines for rabies and dog population management
title_fullStr Development of new recombinant vaccines for rabies and dog population management
title_full_unstemmed Development of new recombinant vaccines for rabies and dog population management
title_short Development of new recombinant vaccines for rabies and dog population management
title_sort development of new recombinant vaccines for rabies and dog population management
topic UCTD
Sustainable Development Goals (SDGs)
Immunocontraceptive
Rabies
Vaccine
Adenomas
Recombinant
url http://hdl.handle.net/2263/110471